Capital Network analyst Emma Ulker assesses recent progress made at () with its lead asset Feraccru.
The drug's approved and marketed in Europe, with a US approval decision pending for July 27.
Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable to tolerate or unresponsive to first-line salt-based oral iron products.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE